Telix Pharmaceuticals Limited
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian Behrenbruch
- Full Time Employees
- 1,136
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Flemington Road North Melbourne VIC Australia 3051
- IPO Date
- Nov 14, 2024
- CIK
- 0002007191
- Website
- telixpharma.com
- Similar Companies
- Business
- Telix Pharmaceuticals Limited operates as a commercial-stage biopharmaceutical firm dedicated to advancing and delivering innovative therapeutic and diagnostic radiopharmaceutical agents. The company strategically focuses on a theranostic approach, combining imaging and treatment to precisely target cancers and certain rare conditions. Headquartered in North Melbourne, Australia, Telix maintains significant global operations across the United States, Europe, and Japan. Among its commercial offerings is Illuccix® (gallium-68 gozetotide injection), a key imaging agent utilized for detecting prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer. Illuccix has secured marketing authorizations in major territories including the United States, Australia, Canada, the United Kingdom, and across Europe. Another recently approved prostate cancer imaging agent, Gozellix®, has commenced its commercial launch in the U.S. Additionally, Telix provides Scintimun® (technetium-99m besilesomab) for imaging osteomyelitis in numerous European countries and Mexico, along with the SENSEI® surgical gamma probe for guided surgery. The company’s robust pipeline includes several late-stage investigational candidates. TLX591, a radio antibody-drug conjugate, is undergoing a pivotal Phase 3 clinical trial for metastatic castration-resistant prostate cancer. For renal (kidney) cancer, the diagnostic agent TLX250-CDx (Zircaix®) received a Complete Response Letter from the U.S. FDA, citing Chemistry, Manufacturing, and Controls deficiencies, despite its prior Breakthrough Therapy designation. TLX250 is being developed as a therapeutic counterpart for kidney cancer. Other significant candidates include TLX101-CDx for brain (glioma) cancer imaging and TLX101 for glioblastoma therapy, alongside TLX592 for targeted alpha therapy in prostate cancer, and TLX090 for metastatic bone pain. Telix also continues to expand its pipeline with novel fibroblast activation protein (FAP)-targeting theranostic agents, initially focusing on bladder cancer. Telix Pharmaceuticals reported strong financial performance in FY2024 with total revenue reaching $783.2 million AUD, predominantly driven by Illuccix sales, and projects FY2025 revenue guidance between $1.18 billion to $1.23 billion AUD ($770 million to $800 million USD). The company, founded in 2015, is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
FDA Alignment to Advance ProstACT Global Phase 3 Trial
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Telix and United Imaging Announce Strategic Theranostics Collaboration
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Why Is Regeneron Stock Sinking Monday?
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 Transcript
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma